Particularly, the combination therapy of relatlimab (anti-LAG-3 mAb; BMS-986016) with nivolumab (anti-PD-1 mAb) has demonstrated impressive clinical effectiveness in melanoma patients unresponsive to anti-PD-1/PD-L1 therapy (87). This evidence concerns the gene LAG3 and melanoma.